Preclinical antiviral drug combination studies utilizing novel orally bioavailable investigational agents for chronic hepatitis B infection: AB-506, a next generation HBV capsid inhibitor, and AB-452, a HBV RNA destabilizer
Mani, N., Li, A.H.L., Ardzinski, A., Bailey, L., Phelps, J.R., Burns, R., Chiu, T., Cole, A.G., Cuconati, A., Dorsey, B.D., Evangelista, E., Gotchev, D., Harasym, T.O., Jarosz, A., Kadhim, S., KondratVolume:
68
Language:
english
Journal:
Journal of Hepatology
DOI:
10.1016/S0168-8278(18)30252-6
Date:
April, 2018
File:
PDF, 52 KB
english, 2018